CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Zepbound (tirzepatide) is only available on ... Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli Lilly, directly. Share on Pinterest Zepbound is a dual ...

Orforglipron is Eli Lilly's pill version of tirzepatide, and the company expects data on the experimental drug by the middle of this year and potential approval as early as the first few months of ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...